Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-n-ethyl-3-((1-dimethyl-amino)ethyl)-n-methylphenylcarbamate
2. 713, Ena
3. 713, Sdz Ena
4. Ena 713
5. Ena 713, Sdz
6. Ena-713
7. Ena713
8. Exelon
9. Hydrogen Tartrate, Rivastigmine
10. Rivastigmine Hydrogen Tartrate
11. Rivastigminetartrate
12. Sdz Ena 713
13. Tartrate, Rivastigmine Hydrogen
1. 123441-03-2
2. Exelon
3. Ena 713 Free Base
4. Prometax
5. Rivastigmine Teva
6. Nimvastid
7. S-rivastigmine
8. Rivastigmine Hexal
9. (s)-rivastigmine
10. (s)-3-(1-(dimethylamino)ethyl)phenyl Ethyl(methyl)carbamate
11. Rivastigmine Sandoz
12. Sdz-ena-713
13. Sdz-212-713
14. [3-[(1s)-1-(dimethylamino)ethyl]phenyl] N-ethyl-n-methylcarbamate
15. M-((s)-1-(dimethylamino)ethyl)phenyl Ethylmethylcarbamate
16. (s)-3-(1-(dimethylamino)ethyl)phenyl Ethylmethylcarbamate
17. Chembl636
18. 3-[(1s)-1-(dimethylamino)ethyl]phenyl N-ethyl-n-methylcarbamate
19. Pki06m3iw0
20. Chebi:8874
21. Ena-713d
22. Ono-2540
23. Sdz-212713
24. 3-[(1s)-1-(dimethylamino)ethyl]phenyl Ethyl(methyl)carbamate
25. Exelon Patch
26. Ethylmethylcarbamic Acid 3-[(1s)-1-(dimethylamino)ethyl]phenyl Ester
27. Sr-05000001475
28. Unii-pki06m3iw0
29. Sdz 212-713
30. Rivastigmine Transdermal System
31. Prometax (tn)
32. Rivastigmine [usan:inn:ban:jan]
33. Rivastigmine.tartrate
34. Rivastigmine Impurity D
35. 3-((1s)-1-(dimethylamino)ethyl)phenyl Ethylmethylcarbamate
36. Rivastigmine [mi]
37. Rivastigmine [inn]
38. Rivastigmine [jan]
39. Carbamic Acid, Ethylmethyl-, 3-((1s)-1-(dimethylamino)ethyl)phenyl Ester
40. Rivastigmine [usan]
41. Schembl2764
42. Rivastigmine [vandf]
43. Rivastigmine [mart.]
44. Ethylmethylcarbamic Acid 3-[1-(dimethylamino)ethyl]phenyl Ester
45. Mls003876822
46. Bidd:gt0316
47. Rivastigmine [usp-rs]
48. Rivastigmine [who-dd]
49. Rivastigmine (jan/usp/inn)
50. Gtpl6602
51. Zinc4413
52. Rivastigmine [ema Epar]
53. Rivastigmine 1 A Pharma
54. Dtxsid7023564
55. Bdbm10620
56. Bdbm11682
57. Amy3808
58. Hms2089h18
59. Hms3715p15
60. Hms3885b18
61. Rivastigmine [orange Book]
62. Rivastigmine [ep Monograph]
63. Rivastigmine [usp Monograph]
64. Mfcd00871496
65. Akos015896334
66. Carbamic Acid, Ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl Ester, (s)-
67. Ac-8250
68. Ccg-221197
69. Cs-0946
70. Db00989
71. Rivastigmine 3m Health Care Ltd
72. Ncgc00167531-03
73. Ncgc00167531-17
74. As-73448
75. Hy-17368
76. Smr002203623
77. R0250
78. S4687
79. (r)-rivastigmine (rivastigmine Ep Impurity D)
80. D03822
81. D82061
82. F10108
83. Ab01275472-01
84. Ab01275472_02
85. Ab01275472_03
86. 101r548
87. Q411887
88. Sr-05000001475-1
89. Sr-05000001475-2
90. W-200966
91. (s)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-n-methylcarbamate
92. [3-[(1s)-1-dimethylaminoethyl]phenyl] N-ethyl-n-methylcarbamate
93. 3-((1s)-1-(dimethylamino)ethyl)phenyl N-ethyl N-methyl Carbamate
94. Ethyl-methyl-carbamic Acid 3-(1-dimethylamino-ethyl)-phenyl Ester
95. Ethyl-methyl-carbamic Acid 3-((r)-1-dimethylamino-ethyl)-phenyl Ester
96. Ethyl-methyl-carbamic Acid 3-((s)-1-dimethylamino-ethyl)-phenyl Ester
97. Carbamic Acid, N-ethyl-n-methyl-, 3-[(1s)-1-(dimethylamino)ethyl]phenyl Ester
98. 2,3-dihydroxybutanedioic Acid; 3-[(1s)-1-(dimethylamino)ethyl]phenyl N-ethyl-n-methylcarbamate
Molecular Weight | 250.34 g/mol |
---|---|
Molecular Formula | C14H22N2O2 |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 250.168127949 g/mol |
Monoisotopic Mass | 250.168127949 g/mol |
Topological Polar Surface Area | 32.8 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 269 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Rivastigmine |
PubMed Health | Rivastigmine |
Drug Classes | Central Nervous System Agent |
Drug Label | Rivastigmine tartrate is a reversible cholinesterase inhibitor and is known chemically as (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate. Rivastigmine tartrate is commonly referred to in the pharmacological... |
Active Ingredient | Rivastigmine tartrate |
Dosage Form | Solution |
Route | oral |
Strength | 2mg/ml |
Market Status | Tentative Approval |
Company | Ranbaxy |
2 of 2 | |
---|---|
Drug Name | Rivastigmine |
PubMed Health | Rivastigmine |
Drug Classes | Central Nervous System Agent |
Drug Label | Rivastigmine tartrate is a reversible cholinesterase inhibitor and is known chemically as (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate. Rivastigmine tartrate is commonly referred to in the pharmacological... |
Active Ingredient | Rivastigmine tartrate |
Dosage Form | Solution |
Route | oral |
Strength | 2mg/ml |
Market Status | Tentative Approval |
Company | Ranbaxy |
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
FDA Label
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
Treatment of dementia
Treatment of dementia
Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
N06DA03
N06DA03
N06DA03
N06DA03
N06DA03
N06DA03
N06DA03
N06DA03
N06DA03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N06 - Psychoanaleptics
N06D - Anti-dementia drugs
N06DA - Anticholinesterases
N06DA03 - Rivastigmine
Route of Elimination
Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.
Volume of Distribution
1.8 to 2.7 L/kg
Clearance
renal cl=2.1-2.8 L/hr
Rivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.
1.5 hours
Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-28
Pay. Date : 2013-03-20
DMF Number : 22974
Submission : 2009-07-22
Status : Active
Type : II
Certificate Number : R1-CEP 2013-354 - Rev 00
Issue Date : 2020-01-23
Type : Chemical
Substance Number : 2629
Status : Valid
Registration Number : 301MF10032
Registrant's Address : Joan Buscala, 10 E-08173 Sant Cugat del Valles, Barcelona, Spain
Initial Date of Registration : 2019-07-19
Latest Date of Registration :
Registrant Name : Samyang Holdings Co., Ltd.
Registration Date : 2017-12-08
Registration Number : 20170821-184-I-519-16(2)
Manufacturer Name : Interquim, SA
Manufacturer Address : c/ Joan Buscallà,10, 08173 Sant Cugat Del Vallès (Barcelona), Spain
Available Reg Filing : ASMF, CA, CN |
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
Registrant Name : Shinil Pharmaceutical Co., Ltd.
Registration Date : 2017-11-27
Registration Number : 20170821-184-I-519-16(1)
Manufacturer Name : Interquim, SA
Manufacturer Address : c/ Joan Buscalla, 10, 08173 Sant Cugat del Vallaes (Barcelona), Spain
Available Reg Filing : ASMF, CA, CN |
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2017-08-21
Registration Number : 20170821-184-I-519-16
Manufacturer Name : Interquim, SA
Manufacturer Address : c/ Joan Buscallà, 10, 08173 Sant Cugat Del Vallès (Barcelona), Spain
Available Reg Filing : ASMF, CA, CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29133
Submission : 2015-03-20
Status : Active
Type : II
Certificate Number : R1-CEP 2015-279 - Rev 00
Issue Date : 2022-09-23
Type : Chemical
Substance Number : 2629
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36529
Submission : 2022-01-31
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-11-12
Pay. Date : 2014-08-07
DMF Number : 24502
Submission : 2011-03-27
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-29
Pay. Date : 2013-09-24
DMF Number : 25871
Submission : 2011-12-22
Status : Active
Type : II
Registration Number : 228MF10192
Registrant's Address : VIA F. BARACCA 19-24060 SAN PAOLO D'ARGON (BERGAMO) ITALY
Initial Date of Registration : 2016-10-05
Latest Date of Registration :
NDC Package Code : 49706-1825
Start Marketing Date : 2013-10-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Essel Bio Co., Ltd.
Registration Date : 2023-04-06
Registration Number : 20210924-184-I-627-20(1)
Manufacturer Name : Erregierre SpA
Manufacturer Address : Via F. Baracca, 19-24060 San Paolo D'Argon (BG), Italy
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-08
Pay. Date : 2013-02-19
DMF Number : 26499
Submission : 2012-09-26
Status : Active
Type : II
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2013-03-22
Registration Number : 20130322-184-I-313-04
Manufacturer Name : Viyash Life Sciences Private Limited
Manufacturer Address : Plot No.1-A/2 & Plot No. 1-A/3, MIDC Taloja Industrial Area, Taloja - 410208 Taluka: Panvel, District RAIGAD. Maharashtra, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22683
Submission : 2009-04-01
Status : Inactive
Type : II
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-28
Pay. Date : 2013-03-20
DMF Number : 22974
Submission : 2009-07-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22683
Submission : 2009-04-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29199
Submission : 2015-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-11-01
Pay. Date : 2015-03-12
DMF Number : 29033
Submission : 2015-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-29
Pay. Date : 2013-09-24
DMF Number : 25871
Submission : 2011-12-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-11-12
Pay. Date : 2014-08-07
DMF Number : 24502
Submission : 2011-03-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29133
Submission : 2015-03-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-08
Pay. Date : 2013-02-19
DMF Number : 26499
Submission : 2012-09-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24485
Submission : 2010-12-23
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-06
Pay. Date : 2013-09-25
DMF Number : 27516
Submission : 2013-09-30
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
90
PharmaCompass offers a list of Rivastigmine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rivastigmine manufacturer or Rivastigmine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rivastigmine manufacturer or Rivastigmine supplier.
PharmaCompass also assists you with knowing the Rivastigmine API Price utilized in the formulation of products. Rivastigmine API Price is not always fixed or binding as the Rivastigmine Price is obtained through a variety of data sources. The Rivastigmine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nimvastid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nimvastid, including repackagers and relabelers. The FDA regulates Nimvastid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nimvastid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nimvastid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nimvastid supplier is an individual or a company that provides Nimvastid active pharmaceutical ingredient (API) or Nimvastid finished formulations upon request. The Nimvastid suppliers may include Nimvastid API manufacturers, exporters, distributors and traders.
click here to find a list of Nimvastid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nimvastid DMF (Drug Master File) is a document detailing the whole manufacturing process of Nimvastid active pharmaceutical ingredient (API) in detail. Different forms of Nimvastid DMFs exist exist since differing nations have different regulations, such as Nimvastid USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nimvastid DMF submitted to regulatory agencies in the US is known as a USDMF. Nimvastid USDMF includes data on Nimvastid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nimvastid USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nimvastid suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nimvastid Drug Master File in Japan (Nimvastid JDMF) empowers Nimvastid API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nimvastid JDMF during the approval evaluation for pharmaceutical products. At the time of Nimvastid JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nimvastid suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nimvastid Drug Master File in Korea (Nimvastid KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nimvastid. The MFDS reviews the Nimvastid KDMF as part of the drug registration process and uses the information provided in the Nimvastid KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nimvastid KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nimvastid API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nimvastid suppliers with KDMF on PharmaCompass.
A Nimvastid CEP of the European Pharmacopoeia monograph is often referred to as a Nimvastid Certificate of Suitability (COS). The purpose of a Nimvastid CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nimvastid EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nimvastid to their clients by showing that a Nimvastid CEP has been issued for it. The manufacturer submits a Nimvastid CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nimvastid CEP holder for the record. Additionally, the data presented in the Nimvastid CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nimvastid DMF.
A Nimvastid CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nimvastid CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nimvastid suppliers with CEP (COS) on PharmaCompass.
A Nimvastid written confirmation (Nimvastid WC) is an official document issued by a regulatory agency to a Nimvastid manufacturer, verifying that the manufacturing facility of a Nimvastid active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nimvastid APIs or Nimvastid finished pharmaceutical products to another nation, regulatory agencies frequently require a Nimvastid WC (written confirmation) as part of the regulatory process.
click here to find a list of Nimvastid suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nimvastid as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nimvastid API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nimvastid as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nimvastid and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nimvastid NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nimvastid suppliers with NDC on PharmaCompass.
Nimvastid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nimvastid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nimvastid GMP manufacturer or Nimvastid GMP API supplier for your needs.
A Nimvastid CoA (Certificate of Analysis) is a formal document that attests to Nimvastid's compliance with Nimvastid specifications and serves as a tool for batch-level quality control.
Nimvastid CoA mostly includes findings from lab analyses of a specific batch. For each Nimvastid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nimvastid may be tested according to a variety of international standards, such as European Pharmacopoeia (Nimvastid EP), Nimvastid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nimvastid USP).